Ibsrela®
Drug - Ibsrela® (tenapanor) [Ardelyx, Inc.]
October 2022
Therapeutic area - GI Motility, Chronic
Approval criteria
- Patient must be 18 years of age and older AND
- Patient has a diagnosis of irritable bowel syndrome with constipation (IBS-C) AND
- Patients does not have known or suspected mechanical gastrointestinal obstruction AND
- Prescriber attests that constipation-causing therapies for other diseases have been reviewed and therapies avoided if possible AND
- Patient has tried and failed at least 4 of the following medical therapies: psyllium, methlycellulose, polycarbophil, wheat dexdrin, magnesium hydoxide, magnesium citrate, sodium phosphate, lactulose, PEG electrolyte solution, docusate, mineral oil, senna, bisacodyl, phosphate enema, mineral oil retention, tap-water enema, glycerin suppository, glycerin-bisacodyl suppository AND
- Patient has tried and failed Linzess, unless contraindicated
Quantity limits
Questions?
MHCP Provider Resource Center 651-431-2700 or 800-366-5411
